1. The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Currently Approved Checkpoint Inhibitors for NSCLC

5. Emerging Therapies: Front-Line NSCLC

6. Emerging Therapies: SCLC

7. Emerging Therapies: Mesothelioma

8. Overview of Immune-Related Adverse Events (irAEs)

9. Baseline Monitoring for irAEs

10. Examples of Patients With Preexisting Medical Conditions Receiving Immunotherapy

11. Additional Monitoring for irAEs

12. Grade-Based Management of irAEs

13. Management of Pneumonitis

14. Management of Diarrhea or Colitis

15. Management of Endocrinopathies

16. Management of Other irAEs

17. Management of Other irAEs (cont)

18. Use of Systemic Steroids

19. Topics for Educating Patients and Caregivers

20. Abbreviations